(Q42616375)

3 November 2017

title

Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial (English)

1 reference

3 November 2017

1 reference

2

1 reference

3 November 2017

1

Ferrendelli JA

1 reference

3 November 2017

Leppik I

3

1 reference

3 November 2017

Morrell MJ

4

1 reference

3 November 2017

Herbeuval A

5

1 reference

3 November 2017

Han J

6

1 reference

3 November 2017

Magnus L

7

1 reference

3 November 2017

publication date

1 December 2003

1 reference

3 November 2017

1 reference

3 November 2017

volume

4

1 reference

3 November 2017

issue

6

1 reference

3 November 2017

page(s)

702-709

1 reference

Prevalence of epilepsy in the elderly: the Rotterdam Study.

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Consensus statements: medical management of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Dose-response effect of levetiracetam 1000 and 2000 mg/day in partial epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Use of levetiracetam in special populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Efficacy of levetiracetam: a review of three pivotal clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Anticonvulsant therapy in the elderly—A need for placebo controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Pharmacologic management of epilepsy in the elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Treatment of Epilepsy in the Elderly.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

Levetiracetam: a different approach to the pharmacotherapy of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.09.007

10.1016/J.YEBEH.2003.09.007

7 January 2021

Identifiers

DOI

1 reference

3 November 2017

1 reference